Cargando…

Genetic and Non-genetic Factors Contributing to the Significant Variation in the Plasma Trough Concentration-to-Dose Ratio of Valproic Acid in Children With Epilepsy

Objective: This study was conducted to evaluate the potential genetic and non-genetic factors contributing to plasma trough concentration-to-dose (C(0)/D) ratio of valproic acid (VPA) in pediatric patients with epilepsy. Study Design: A single-center, retrospective cohort study was performed by coll...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Ze-Yue, Guo, Hong-Li, Li, Ling, Zhang, Min, Jing, Xia, Xu, Ze-Jun, Qiu, Jin-Chun, Lu, Xiao-Peng, Ding, Xuan-Sheng, Chen, Feng, Xu, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7855978/
https://www.ncbi.nlm.nih.gov/pubmed/33553069
http://dx.doi.org/10.3389/fped.2020.599044
_version_ 1783646213033164800
author Xu, Ze-Yue
Guo, Hong-Li
Li, Ling
Zhang, Min
Jing, Xia
Xu, Ze-Jun
Qiu, Jin-Chun
Lu, Xiao-Peng
Ding, Xuan-Sheng
Chen, Feng
Xu, Jing
author_facet Xu, Ze-Yue
Guo, Hong-Li
Li, Ling
Zhang, Min
Jing, Xia
Xu, Ze-Jun
Qiu, Jin-Chun
Lu, Xiao-Peng
Ding, Xuan-Sheng
Chen, Feng
Xu, Jing
author_sort Xu, Ze-Yue
collection PubMed
description Objective: This study was conducted to evaluate the potential genetic and non-genetic factors contributing to plasma trough concentration-to-dose (C(0)/D) ratio of valproic acid (VPA) in pediatric patients with epilepsy. Study Design: A single-center, retrospective cohort study was performed by collecting data from 194 children aged 1–14 years between May 2018 and November 2018. The oral solution (n = 135) group and the sustained-release (SR) tablet group (n = 59) were defined, and the plasma VPA C(0) was measured. Twenty-six single-nucleotide polymorphisms (SNPs) were chosen for genotyping with the MassARRAY system. A multiple logistic regression model was used for data analysis. Results: Body weight (BW) and age were positively correlated with the C(0)/D ratio in 194 patients, but the positive correlation disappeared after the patients were divided into oral solution and SR tablet subgroups. The average C(0)/D ratio was significantly increased by 2.11-fold (P = 0.000) in children who took VPA SR tablets compared with children who were administered VPA oral solutions. No significant association between genetic variants and the C(0)/D ratio was found, even for the five well-studied SNPs, namely UGT2B7 G211T, C802T, C161T, T125C, and CYP2C9(*)3 A1075C. However, a significant association between the C(0)/D ratio and UGT1A6/9 Del>A (rs144486213) was observed in the VPA oral solution group, but not in the VPA SR tablet group. Conclusions: The dosage forms of sodium valproate, rather than BW, age, or genetic polymorphisms, significantly affected the VPA C(0)/D ratios in pediatric patients with epilepsy. Based on our findings, switching the dosage form between solution and SR tablet should be performed cautiously. Total daily dose adjustment should be considered, and the plasma concentration, seizure-control effect, and adverse drug reaction should also be monitored very closely.
format Online
Article
Text
id pubmed-7855978
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78559782021-02-04 Genetic and Non-genetic Factors Contributing to the Significant Variation in the Plasma Trough Concentration-to-Dose Ratio of Valproic Acid in Children With Epilepsy Xu, Ze-Yue Guo, Hong-Li Li, Ling Zhang, Min Jing, Xia Xu, Ze-Jun Qiu, Jin-Chun Lu, Xiao-Peng Ding, Xuan-Sheng Chen, Feng Xu, Jing Front Pediatr Pediatrics Objective: This study was conducted to evaluate the potential genetic and non-genetic factors contributing to plasma trough concentration-to-dose (C(0)/D) ratio of valproic acid (VPA) in pediatric patients with epilepsy. Study Design: A single-center, retrospective cohort study was performed by collecting data from 194 children aged 1–14 years between May 2018 and November 2018. The oral solution (n = 135) group and the sustained-release (SR) tablet group (n = 59) were defined, and the plasma VPA C(0) was measured. Twenty-six single-nucleotide polymorphisms (SNPs) were chosen for genotyping with the MassARRAY system. A multiple logistic regression model was used for data analysis. Results: Body weight (BW) and age were positively correlated with the C(0)/D ratio in 194 patients, but the positive correlation disappeared after the patients were divided into oral solution and SR tablet subgroups. The average C(0)/D ratio was significantly increased by 2.11-fold (P = 0.000) in children who took VPA SR tablets compared with children who were administered VPA oral solutions. No significant association between genetic variants and the C(0)/D ratio was found, even for the five well-studied SNPs, namely UGT2B7 G211T, C802T, C161T, T125C, and CYP2C9(*)3 A1075C. However, a significant association between the C(0)/D ratio and UGT1A6/9 Del>A (rs144486213) was observed in the VPA oral solution group, but not in the VPA SR tablet group. Conclusions: The dosage forms of sodium valproate, rather than BW, age, or genetic polymorphisms, significantly affected the VPA C(0)/D ratios in pediatric patients with epilepsy. Based on our findings, switching the dosage form between solution and SR tablet should be performed cautiously. Total daily dose adjustment should be considered, and the plasma concentration, seizure-control effect, and adverse drug reaction should also be monitored very closely. Frontiers Media S.A. 2021-01-20 /pmc/articles/PMC7855978/ /pubmed/33553069 http://dx.doi.org/10.3389/fped.2020.599044 Text en Copyright © 2021 Xu, Guo, Li, Zhang, Jing, Xu, Qiu, Lu, Ding, Chen and Xu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pediatrics
Xu, Ze-Yue
Guo, Hong-Li
Li, Ling
Zhang, Min
Jing, Xia
Xu, Ze-Jun
Qiu, Jin-Chun
Lu, Xiao-Peng
Ding, Xuan-Sheng
Chen, Feng
Xu, Jing
Genetic and Non-genetic Factors Contributing to the Significant Variation in the Plasma Trough Concentration-to-Dose Ratio of Valproic Acid in Children With Epilepsy
title Genetic and Non-genetic Factors Contributing to the Significant Variation in the Plasma Trough Concentration-to-Dose Ratio of Valproic Acid in Children With Epilepsy
title_full Genetic and Non-genetic Factors Contributing to the Significant Variation in the Plasma Trough Concentration-to-Dose Ratio of Valproic Acid in Children With Epilepsy
title_fullStr Genetic and Non-genetic Factors Contributing to the Significant Variation in the Plasma Trough Concentration-to-Dose Ratio of Valproic Acid in Children With Epilepsy
title_full_unstemmed Genetic and Non-genetic Factors Contributing to the Significant Variation in the Plasma Trough Concentration-to-Dose Ratio of Valproic Acid in Children With Epilepsy
title_short Genetic and Non-genetic Factors Contributing to the Significant Variation in the Plasma Trough Concentration-to-Dose Ratio of Valproic Acid in Children With Epilepsy
title_sort genetic and non-genetic factors contributing to the significant variation in the plasma trough concentration-to-dose ratio of valproic acid in children with epilepsy
topic Pediatrics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7855978/
https://www.ncbi.nlm.nih.gov/pubmed/33553069
http://dx.doi.org/10.3389/fped.2020.599044
work_keys_str_mv AT xuzeyue geneticandnongeneticfactorscontributingtothesignificantvariationintheplasmatroughconcentrationtodoseratioofvalproicacidinchildrenwithepilepsy
AT guohongli geneticandnongeneticfactorscontributingtothesignificantvariationintheplasmatroughconcentrationtodoseratioofvalproicacidinchildrenwithepilepsy
AT liling geneticandnongeneticfactorscontributingtothesignificantvariationintheplasmatroughconcentrationtodoseratioofvalproicacidinchildrenwithepilepsy
AT zhangmin geneticandnongeneticfactorscontributingtothesignificantvariationintheplasmatroughconcentrationtodoseratioofvalproicacidinchildrenwithepilepsy
AT jingxia geneticandnongeneticfactorscontributingtothesignificantvariationintheplasmatroughconcentrationtodoseratioofvalproicacidinchildrenwithepilepsy
AT xuzejun geneticandnongeneticfactorscontributingtothesignificantvariationintheplasmatroughconcentrationtodoseratioofvalproicacidinchildrenwithepilepsy
AT qiujinchun geneticandnongeneticfactorscontributingtothesignificantvariationintheplasmatroughconcentrationtodoseratioofvalproicacidinchildrenwithepilepsy
AT luxiaopeng geneticandnongeneticfactorscontributingtothesignificantvariationintheplasmatroughconcentrationtodoseratioofvalproicacidinchildrenwithepilepsy
AT dingxuansheng geneticandnongeneticfactorscontributingtothesignificantvariationintheplasmatroughconcentrationtodoseratioofvalproicacidinchildrenwithepilepsy
AT chenfeng geneticandnongeneticfactorscontributingtothesignificantvariationintheplasmatroughconcentrationtodoseratioofvalproicacidinchildrenwithepilepsy
AT xujing geneticandnongeneticfactorscontributingtothesignificantvariationintheplasmatroughconcentrationtodoseratioofvalproicacidinchildrenwithepilepsy